virologic response

Related by string. virologic responses * ViroLogic . Virologic : sustained virologic response . virologic suppression . virologic failure / Responses . re sponse . RESPONSE : Computer Emergency Response . Emergency Response Team * virologic response EVR . rapid virologic response . Sustained Virologic Response . Sustained virologic response . Rapid Virologic Response *

Related by context. All words. (Click for frequent words.) 77 virologic failure 76 virological response 75 sustained virologic response 73 sustained virological response 73 viral suppression 73 SVR# 72 HBeAg seroconversion 71 virologic 71 virological failure 70 HIV RNA 70 seroconversion 70 peginterferon alfa 2a 70 complete cytogenetic response 70 undetectable HCV RNA 70 undetectable viral load 69 CR nPR 69 viral kinetics 69 HBeAg 69 rapid virologic response 69 PASI scores 69 chlorambucil 69 CIMZIA TM 69 pCR 69 lumbar spine BMD 69 virologic responses 68 cytogenetic response 68 serum HBV DNA 68 posaconazole 68 definite stent thrombosis 68 prospectively defined 68 CANCIDAS 68 mRCC 68 PegIFN RBV 68 genotypic resistance 68 tipranavir 68 virological suppression 68 lopinavir r 68 NNRTI resistance 68 mg kg dose 68 ACR# response 68 CCyR 68 serum urate levels 68 HCV RNA 68 liver histology 68 antiviral efficacy 68 mg BID 68 FOLPI 68 clinically meaningful improvement 68 CD4 + cell 68 Pegasys plus Copegus 67 oxycodone CR 67 severe neutropenia 67 recurrent VTE 67 platelet reactivity 67 biochemical relapse 67 undetectable HBV DNA 67 decitabine 67 fosamprenavir 67 platelet inhibition 67 APTIVUS r 67 relapsed MM 67 tolvaptan 67 ADAS cog 67 ACR# responses 67 hematologic toxicity 67 Non inferiority 67 detectable HCV RNA 67 bosentan 66 ribavirin therapy 66 PSADT 66 mg/m2 dose 66 tipranavir r 66 peginterferon 66 PREZISTA r 66 LEXIVA r 66 alanine aminotransferase ALT 66 HbA 1c 66 neutrophil counts 66 timepoint 66 Subgroup analysis 66 DAPT 66 HAQ DI 66 ABC/3TC 66 biochemical recurrence 66 HBeAg positive 66 median PFS 66 CIMZIA ™ 66 adalimumab 66 hepatic fibrosis 66 Kaplan Meier analysis 66 serum phosphate 66 lopinavir r arm 66 TMC# r 66 adefovir 66 radiographic progression 66 HBV DNA 66 ritonavir boosted 66 morphometric vertebral fractures 66 annualized relapse 66 binary restenosis 66 noninferiority 66 MADRS score 66 virologic suppression 66 posttreatment 66 baseline HbA1c 66 HbA1c levels 66 seropositive patients 66 virologic response EVR 66 nephrotoxicity 66 serum testosterone 66 complete cytogenetic 66 Index CDAI 66 peginterferon alfa 2b 66 serum urate 66 eplerenone 66 ribavirin RBV 66 plasma HCV RNA 65 HBV DNA levels 65 evaluable subjects 65 serum HCV RNA 65 progression TTP 65 EDSS score 65 chemoradiotherapy 65 fluvastatin 65 mycophenolate mofetil 65 Free Survival PFS 65 mCRC patients 65 docetaxel chemotherapy 65 antibody titers 65 tiotropium 65 aminotransferases 65 doxorubicin docetaxel 65 seroprotection 65 abacavir lamivudine 65 nonresponders 65 paricalcitol 65 XIENCE V PROMUS Stent 65 androgen deprivation 65 tirofiban 65 LVEF 65 plasma uric acid 65 tumor recurrence 65 FOLFIRI 65 protease inhibitor PI 65 tapentadol ER 65 Doxil ® 65 serum phosphorus 65 certolizumab 65 imatinib therapy 65 SCr 65 mg QD 65 CIN3 65 mcg BID 65 serum clusterin levels 65 riociguat 65 divalproex sodium 65 gout flares 65 IPSS 65 secondary efficacy endpoints 65 postoperative mortality 65 TDF FTC 65 FOLFOX6 65 neoadjuvant chemotherapy 65 sUA 65 TEAEs 65 ALT flares 65 FOLFOX4 65 KRAS status 65 insulin detemir 65 remission CR 65 experienced virologic failure 65 raltegravir 65 secondary efficacy endpoint 65 viremia 65 hsCRP levels 65 QTc 65 daunorubicin 65 Sustained virologic response 64 β blockers 64 viral load 64 desvenlafaxine succinate 64 tumor shrinkage 64 pegylated interferon alfa 64 null responders 64 peg interferon 64 DMARD 64 #mg BID [001] 64 mucosal healing 64 CIMZIA TM certolizumab pegol 64 Crohn Disease Activity 64 antibody titer 64 serum phosphate levels 64 HbA 1c levels 64 hepatitis C genotype 64 cEVR 64 Flu Cy 64 pramipexole 64 hemoglobin A1c levels 64 postoperative chemotherapy 64 pegylated liposomal doxorubicin 64 HCV genotype 1 64 Betaferon ® 64 HCV genotype 64 serum creatinine levels 64 teriflunomide 64 nitazoxanide 64 IFN α 64 R# #mg BID 64 NATRECOR ® 64 NLX P# 64 ibandronate 64 concomitant medications 64 invasive candidiasis 64 anemia hemoglobin 64 BARACLUDE ® 64 HBeAg negative patients 64 cytogenetic responses 64 intravenous bisphosphonates 64 dose cytarabine 64 HBeAg positive patients 64 transaminase elevations 64 XELOX 64 plus ribavirin 64 mcg albinterferon alfa 2b 64 retinal thickness 64 PSA nadir 64 IV bisphosphonates 64 MCyR 64 clodronate 64 femoral neck BMD 64 comparator arm 64 comparator PI r 64 glycated hemoglobin levels 64 steroid dexamethasone 64 EDSS scores 64 HSCT 64 EGFR TKI 64 ACTEMRA TM 64 antiretroviral naive 64 lymphadenectomy 64 adjunctive placebo 64 QTc prolongation 64 neurologic progression 64 response CCyR 64 favorable tolerability 64 ipsilateral stroke 64 corrected QT interval 64 % CI #.#-#.# [003] 64 YMRS 64 interferon ribavirin 64 low dose cytarabine 64 Pred Forte 63 rapid virological response 63 Virologic 63 tocilizumab 63 anti leukemic 63 log# copies mL 63 metastatic RCC 63 macroalbuminuria 63 amoxicillin clavulanate 63 HDRS 63 serum PSA 63 timepoints 63 P = .# 63 atheroma volume 63 OAB symptoms 63 mg TID 63 lamivudine refractory patients 63 thromboembolic events 63 NATRECOR R 63 APTIVUS R 63 oral FTY# 63 heavily pretreated patients 63 iniparib 63 HBeAg negative 63 temsirolimus 63 relapsed AML 63 rFVIIa 63 APTIVUS 63 metastatic renal cell carcinoma 63 viral titers 63 intensive statin therapy 63 carboplatin paclitaxel 63 prospectively stratified 63 azacitidine 63 trastuzumab Herceptin ® 63 goserelin 63 5-FU/LV 63 p = NS 63 darunavir 63 achieved statistical significance 63 eculizumab therapy 63 glycemia 63 complete remissions 63 standard chemotherapy regimen 63 alanine aminotransferase 63 periprocedural 63 pegylated interferon 63 active comparator 63 cytopenias 63 tipranavir ritonavir 63 IELT 63 antiviral activity 63 solifenacin 63 copies mL 63 elevated ALT 63 invasive aspergillosis 63 5FU 63 hemorrhagic complications 63 PEG IFN 63 dexmedetomidine 63 darunavir ritonavir 63 serum concentrations 63 canakinumab 63 DLTs 63 spontaneous bowel movements 63 plus dexamethasone 63 achieved ACR# 63 inflammatory lesions 63 adriamycin 63 carotid IMT 63 ertapenem 63 baminercept 63 REYATAZ r arm 63 locoregional recurrence 63 FluCAM 63 atazanavir ritonavir 63 OGTT 63 pegylated interferon alpha 63 IBDQ 63 Hb A1C 63 RRMS patients 63 serum potassium 63 NPH insulin 63 Lucentis monotherapy 63 Psoriasis Area 63 moderate renal impairment 63 NRTI 63 TNF antagonist 63 dapagliflozin plus 63 μmol L 63 Pegylated Liposomal Doxorubicin 63 prostate cancer CaP 63 ALT normalization 63 apremilast 63 IFN alfa 63 log# reduction 63 adenoma recurrence 63 Hematologic toxicity 63 VELCADE melphalan 63 8mg/kg 63 cabazitaxel 63 micafungin 63 serologically active patients 63 TAXUS Stent 63 dasatinib 63 aspartate aminotransferase 63 T2DM 63 IU mL 63 oblimersen 63 DOXIL 63 RAPAFLO R 63 serum ALT 63 postintervention 63 nab paclitaxel 63 alteplase 63 Viral load 63 ximelagatran 63 Virologic failure 62 HBsAg 62 gefitinib 62 bisphosphonate therapy 62 lopinavir 62 methotrexate monotherapy 62 placebo controlled clinical 62 postoperative complication 62 #mg dose [002] 62 tumor regressions 62 pegylated interferon alfa 2b 62 intravascular hemolysis 62 PROMACTA 62 Dasatinib 62 febrile neutropenia 62 antiretroviral naïve 62 virologically 62 free survival PFS 62 cinacalcet 62 antitumor activity 62 p = .# [002] 62 mcg Albuferon 62 efficacy endpoint 62 intravenous dosing 62 Cmax 62 posttransplant 62 leukopenia 62 epithelial ovarian cancer 62 CDAI 62 serum phosphorous 62 dose dexamethasone 62 events AEs 62 low dose ritonavir 62 randomized multicenter trial 62 immune reconstitution 62 #mg dose [001] 62 creatinine clearance 62 elagolix 62 tamsulosin 62 pomalidomide 62 myelosuppression 62 undetectable viral 62 #mg BID [003] 62 symptomatic VTE 62 nodular partial response 62 R0 resection 62 QTc interval 62 HbA1C 62 receiving VICTRELIS 62 NAbs 62 REYATAZ r 62 eptifibatide 62 subanalysis 62 dose atorvastatin 62 Traficet EN 62 heavily pretreated 62 baseline CD4 62 HCV RESPOND 2 62 alfa 2a 62 ACZ# 62 reinfarction 62 lamivudine 62 fondaparinux 62 GERD symptom 62 laboratory abnormalities 62 glycated hemoglobin HbA1c 62 AGILECT R 62 p = #.# [003] 62 receiving golimumab 62 A1c levels 62 PegIFN 62 symptomatic intracranial hemorrhage 62 Baseline characteristics 62 antitumor effect 62 ATACAND 62 CR CRu 62 mg ustekinumab 62 mapatumumab 62 PREZISTA ritonavir 62 intravenous cyclophosphamide 62 plus methotrexate 62 FDA defined valvulopathy 62 LPV r 62 TPV r 62 plasma concentrations 62 Lupuzor ™ 62 idarubicin 62 transaminases 62 cardiac toxicity 62 fulvestrant 62 QTcF 62 glycosylated hemoglobin HbA1c 62 extrapyramidal symptoms 62 Durezol 62 #.#mg/dL 62 DAS# remission 62 achieved sustained virological 62 Elitek 62 severe exacerbations 62 ULORIC 62 chlamydial infection 62 urate lowering therapy 62 EBRT 62 AZT zidovudine Retrovir 62 MMSE score 62 mTSS 62 androgen suppression 62 ADAS Cog 62 pneumonectomy 62 lanthanum carbonate 62 secondary endpoint 62 renal toxicity 62 urinary N telopeptide 62 BENICAR HCT 62 sunitinib 62 vertebral fracture 62 plus MTX 62 univariate analysis 62 stage IIIb IV 62 vicriviroc 62 severe rotavirus gastroenteritis 61 Rating Scale MADRS 61 AST ALT 61 glycated hemoglobin 61 enfuvirtide 61 subgroup analyzes 61 dosage regimens 61 SUVmax 61 anagrelide 61 methotrexate therapy 61 postmenopausal osteoporotic women 61 beta blocker therapy 61 BEACOPP 61 stage IIIB 61 sorafenib Nexavar 61 virologic breakthrough 61 PreCISe study 61 ALT elevations 61 INCB# [001] 61 mcg dose 61 teriparatide 61 F FDG PET 61 Subgroup analyzes 61 dosing cohorts 61 degarelix 61 flutamide 61 TRANSFORMS 61 ISENTRESS 61 myocardial reperfusion 61 limiting toxicity 61 locoregional 61 PCa 61 Pegylated Interferon 61 gemcitabine Gemzar 61 serum uric acid 61 tamoxifen therapy 61 chloride secretion 61 everolimus eluting stents 61 sulfasalazine 61 topotecan 61 paroxysmal AF 61 dose cohorts 61 DAS# CRP 61 trough FEV1 61 serum prostate 61 HER2 expression 61 specific antigen PSA 61 STRIDE PD 61 colorectal adenoma 61 oral diclofenac 61 zoledronic acid 61 nonoperative treatment 61 nelfinavir 61 pyrazinamide 61 Telbivudine 61 Retreatment 61 #mg/day [001] 61 Montgomery Asberg Depression 61 infliximab 61 salmeterol HFA MDI 61 liver transplant recipients 61 paraprotein 61 CDAI score 61 antihypertensive therapy 61 % CI #.#-#.# [007] 61 Ophena TM 61 angiographic outcomes 61 tolterodine ER 61 serum calcium levels 61 Pemetrexed 61 nucleoside naive 61 cisplatin vinorelbine 61 dose cohort 61 recurrent glioblastoma multiforme 61 peg IFN 61 entecavir 61 Thal Dex 61 #mg BID [002] 61 median survivals 61 CsA 61 MoxDuo TM IR 61 efavirenz EFV 61 locoregional disease 61 trials RCTs 61 neutrophil count 61 FOLFIRINOX 61 nilotinib 61 splenectomized patients 61 analgesic efficacy 61 octreotide LAR 61 CNS LS 61 -#.# log# 61 gemcitabine carboplatin 61 CMV disease 61 leukemia AML 61 mg dose 61 Expanded Disability Status 61 ARCOXIA 61 NYHA functional class 61 Natalizumab 61 HAMD 61 Pharmacokinetic parameters 61 neoadjuvant 61 nonfatal MI 61 aminotransferase levels 61 serum IGF 61 parkinsonian symptoms 61 elotuzumab 61 lactate dehydrogenase LDH 61 viral loads 61 Stent thrombosis 61 PRADAXA 61 mg BID dose 61 rimonabant #mg 61 discontinuations due 61 peginterferon alfa 2a #KD 61 bezafibrate 61 plasma pharmacokinetics 61 nadolol 61 eosinophil count 61 piperacillin tazobactam 61 HBeAg negative chronic hepatitis 61 statistical significance p 61 PREZISTA r arm 61 dacarbazine 61 GOUT 61 Bezielle 61 recurrent GBM 61 K ras mutations 61 antidepressant efficacy 61 metastatic malignant melanoma 61 corticosteroid therapy 61 incidence ≥ 61 CMV infection 61 dose limiting toxicities 61 inhibitor RG# 61 microbiological eradication 61 caspofungin 61 clinically localized prostate 61 placebo dexamethasone 61 ug dose 61 adjuvant tamoxifen 61 Pharmacokinetic 61 taxane chemotherapy 61 advanced adenomas 61 etanercept 61 Hepatotoxicity 61 endoscopic remission 61 noninferior 61 levodopa therapy 61 telbivudine 61 glycosylated hemoglobin levels 61 Nilotinib 61 serum cortisol 61 PANSS scores 61 VADT 61 Toxicities 61 CYPHER Stent 61 lymphocyte counts 61 transgene expression 61 oral rivaroxaban 61 proteinuria 61 PAOD 61 cardiotoxicity 61 neoadjuvant therapy 61 multivariable analysis 61 atherogenic dyslipidemia 61 hemoglobin A1c HbA1c 61 interferon beta therapy 61 ACR# ACR# 61 PRADAXA #mg 61 pharmacokinetic characteristics 61 GnRH agonist 61 fasting plasma glucose FPG 61 acromegalic patients 61 lymphocytosis 61 KRAS mutant tumors 61 dose cyclophosphamide 61 CK MB 61 spirometric 61 prostate cancer PCa 61 Neoadjuvant 61 fluticasone salmeterol 61 Postoperative 61 unboosted 61 Pegasys ® 60 periprocedural MI 60 CRESTOR #mg 60 achieved CCyR 60 prior relapsers 60 T2 lesions 60 alicaforsen enema 60 Secondary efficacy endpoints 60 transaminase levels 60 LV dysfunction 60 cART 60 dalteparin 60 Ishak fibrosis score 60 ALND 60 iPTH 60 liposomal amphotericin B 60 #mg/day [002] 60 nondiabetic patients 60 venlafaxine XR 60 serum aminotransferase levels 60 Peg IFN 60 RLS symptoms 60 doripenem 60 oral Hycamtin 60 rt PA 60 EDARBI 60 imipenem 60 composite endpoint 60 sotalol 60 dosing cohort 60 COMBIVIR 60 FFNS 60 FOLFOX 60 colorectal liver metastases 60 squamous histology 60 HNSCC 60 NIH CPSI 60 operable breast cancer 60 mRS 60 Taxotere ® 60 concurrent chemoradiation 60 hypofractionated radiation 60 ancrod 60 irbesartan 60 alpha 2a 60 angiographic restenosis 60 neurodevelopmental outcome 60 vandetanib 60 incontinence episodes 60 relapsers 60 FOLPI regimen 60 DAS# [002] 60 mcg mL 60 recurrent genital herpes 60 KRAS mutations occur 60 endophthalmitis 60 p# biomarker 60 imatinib 60 neoadjuvant treatment 60 recurrent venous thromboembolism 60 1mg dose 60 iloprost 60 plasma cortisol 60 HPV-#/# 60 salmeterol fluticasone 60 olmesartan 60 seropositivity 60 COPD exacerbations 60 urate levels 60 metabolic parameters 60 platelet inhibitor 60 unfractionated heparin UFH 60 FEV1 60 relapsed ovarian cancer 60 baseline LDH 60 Sustained Virologic Response 60 PROSTVAC VF 60 hypoglycemic events 60 endometrial carcinoma 60 AVODART 60 thyroglobulin 60 lymphopenia 60 paliperidone ER 60 interferon alfa 60 bortezomib 60 concomitant antibiotics 60 phase IIb trial 60 Monotherapy 60 CP CPPS 60 dexamethasone Decadron 60 infarct size 60 ug kg 60 acute gout flares 60 trimethoprim sulfamethoxazole 60 doxorubicin cyclophosphamide 60 docetaxel 60 subtrochanteric 60 highly emetogenic 60 evaluable patients 60 pharmacokinetics PK 60 sitaxsentan 60 neointimal hyperplasia 60 RLAI 60 cediranib 60 HAM D# scores 60 Patency 60 placebo controlled trials 60 DMARD therapy 60 Events MACE 60 coinfected 60 disease progression 60 EXJADE 60 rizatriptan 60 TMC# [001] 60 Median PFS 60 HRQL 60 plasma kallikrein inhibitor 60 Ozarelix 60 galiximab 60 hip BMD 60 neurocognitive function 60 intermittent dosing 60 sirolimus eluting stent 60 univariate analyzes 60 Fludarabine 60 genotype 1b 60 d4T stavudine Zerit 60 CIN2 + 60 cells uL 60 COPAXONE R 60 grade cervical intraepithelial 60 quetiapine XR 60 Helicobacter pylori eradication 60 chemoradiation therapy 60 fasting glucose levels 60 RECIST Response Evaluation Criteria 60 gadolinium enhancing lesions 60 INC# 60 troponin T 60 plus prednisone 60 bronchodilation 60 creatinine ratio 60 MYDICAR ® 60 interferon therapy 60 hypoglycemic episodes 60 INCB# [003] 60 deferiprone 60 QTc intervals 60 tolerability 60 ACR# [002] 60 octreotide 60 mesalamine granules 60 MIRCERA 60 quetiapine 60 insulin degludec 60 4mg/kg 60 nicardipine 60 pulmonary exacerbations 60 Febrile neutropenia 60 plasma renin activity 60 HCV SPRINT 60 #mg QD [002] 60 edifoligide 60 estramustine 60 arterial thickening 60 antimicrobial prophylaxis 60 colesevelam HCl 60 dopaminergic therapy 60 CRp 60 antitumor efficacy 60 graft dysfunction 60 HbA1c 60 Scale EDSS 60 ara C 60 HOMA IR 60 ARB telmisartan 60 mitoxantrone 60 lipid lowering therapy 60 MADIT CRT trial 60 response pCR 60 tumor regression 60 perioperative mortality 60 dose ritonavir 60 elacytarabine 60 estimated glomerular filtration 60 intact parathyroid hormone 60 inotropic 60 Fludara 60 nanomolar 60 HAART regimen 60 Capacity FVC 60 delayed CINV 60 HER2 overexpression 60 infliximab therapy 60 lacosamide 60 thromboembolic complications 60 pentoxifylline 60 CYP#D# genotype 60 postprocedure 60 tumor necrosis 60 Secondary endpoints 60 statin monotherapy 60 anastrozole 60 CYPHER ® Sirolimus eluting 60 metastatic CRC 60 oral olanzapine 60 CYPHER R Sirolimus eluting 60 Erlotinib 60 distant metastases 60 tenofovir emtricitabine 60 NNRTIs 60 thrombocytopenic 60 fasting plasma glucose 60 tumor histology 60 clinically meaningful reductions 60 left ventricular dysfunction 60 KRAS wild 60 mutated KRAS 60 non squamous NSCLC 60 hour bronchodilation 60 #mg/m# [001] 60 curative resection 60 Negative Syndrome 60 events SAEs 60 clinically meaningful efficacy 60 graft patency 60 oral allopurinol 60 idraparinux 60 Disease Progression 60 hematologic parameters 60 prespecified secondary 60 vasomotor symptoms 60 argatroban 60 undetectable viral loads 60 fibrosis progression 60 partial remissions 60 mg kg cohorts 60 nucleoside naive patients 60 pelvic lymphadenectomy 60 3TC lamivudine Epivir 60 hemoglobin concentrations 60 fibrinolytic 60 MS relapses 60 Nesiritide 60 hypokalemia 60 resected pancreatic cancer 60 nonvertebral fracture 60 RE LY 60 seroconverted 60 TLUS 60 GSK# [001] 60 preintervention 60 antipsychotic efficacy 60 fibrinolysis 60 overlapping toxicities 60 relapsing MS 60 Raptiva r 60 elevated serum creatinine 60 hemoglobin concentration 60 Recurrence Score 60 Peginterferon Alfa 2a 60 serum creatinine 60 perioperative complications 60 HAART regimens 60 antiangiogenic therapy 60 microalbuminuria 60 rFSH 60 virologic failures 60 neostigmine 60 somatostatin analog 60 serum sodium 60 HAM D# 60 dose regimens 60 elevated LDH 59 paclitaxel eluting stents 59 PHPT 59 Solid Tumors criteria 59 oral Xeloda 59 blood Phe 59 aldosterone antagonist 59 serum PTH 59 cardiac repolarization 59 leukocyte count 59 nevirapine Viramune 59 rituximab monotherapy 59 Torisel 59 undetectable virus HCV 59 Y BOCS 59 ropinirole 59 EDEMA3 trial 59 mcg QD 59 adjuvant radiotherapy 59 viral kinetic 59 glatiramer acetate 59 node metastases 59 CrCl 59 indinavir 59 ribavirin USP 59 CI -#.# 59 candidemia 59 multivariate Cox 59 VcMP 59 Fulvestrant 59 antibody responses 59 lymph node dissection 59 clinically meaningful improvements 59 Q#IR 59 zotarolimus eluting stent 59 Kaplan Meier curve 59 pegylated interferons 59 Phase 2a trial 59 intraocular inflammation 59 statistically significant p 59 chemotherapeutic regimens 59 d4T 59 fluorouracil 59 dose proportionality 59 glomerular filtration 59 baseline A1C 59 hematological parameters 59 log# 59 Naive Patients 59 #.#ng/ml 59 CPAP adherence 59 cidofovir 59 bendamustine

Back to home page